MX2007004699A - Derivados de indol y bencimidazol. - Google Patents

Derivados de indol y bencimidazol.

Info

Publication number
MX2007004699A
MX2007004699A MX2007004699A MX2007004699A MX2007004699A MX 2007004699 A MX2007004699 A MX 2007004699A MX 2007004699 A MX2007004699 A MX 2007004699A MX 2007004699 A MX2007004699 A MX 2007004699A MX 2007004699 A MX2007004699 A MX 2007004699A
Authority
MX
Mexico
Prior art keywords
indole
compounds
benzimidazole derivatives
new
pharmaceutically acceptable
Prior art date
Application number
MX2007004699A
Other languages
English (en)
Spanish (es)
Inventor
Weibo Wang
Yi Xia
Rustum S Boyce
Hongyan Guo
Annette O Walter
Kris G Mendenhall
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of MX2007004699A publication Critical patent/MX2007004699A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
MX2007004699A 2004-10-19 2005-10-14 Derivados de indol y bencimidazol. MX2007004699A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62038504P 2004-10-19 2004-10-19
PCT/US2005/036803 WO2006049835A2 (en) 2004-10-19 2005-10-14 Indole and benzimidazole derivatives

Publications (1)

Publication Number Publication Date
MX2007004699A true MX2007004699A (es) 2007-06-14

Family

ID=36123937

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004699A MX2007004699A (es) 2004-10-19 2005-10-14 Derivados de indol y bencimidazol.

Country Status (11)

Country Link
US (2) US7608723B2 (enExample)
EP (2) EP1807399A2 (enExample)
JP (1) JP2008517057A (enExample)
KR (1) KR20070072598A (enExample)
CN (1) CN101233115A (enExample)
AU (1) AU2005301133A1 (enExample)
BR (1) BRPI0517314A (enExample)
CA (1) CA2584979A1 (enExample)
MX (1) MX2007004699A (enExample)
RU (1) RU2007118523A (enExample)
WO (1) WO2006049835A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3947758B2 (ja) * 2003-03-07 2007-07-25 アストラゼネカ アクチボラグ 新規縮合ヘテロサイクル及びその使用
UA84954C2 (ru) * 2004-07-22 2008-12-10 Astrazeneca Ab Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
AU2005273705B8 (en) * 2004-08-18 2010-01-28 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer
EP1807399A2 (en) * 2004-10-19 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Indole and benzimidazole derivatives
US20100093767A1 (en) * 2004-12-03 2010-04-15 Takeda San Diego, Inc. Mitotic Kinase Inhibitors
CA2668661A1 (en) * 2006-11-13 2008-05-29 Novartis Ag Substituted pyrazole and triazole compounds as ksp inhibitors
MX2009007260A (es) * 2007-01-05 2009-07-10 Novartis Ag Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5).
DE102007037579B4 (de) 2007-08-09 2012-05-16 Emc Microcollections Gmbh Neue Benzimidazol-2-yl-alkylamine und ihre Anwendung als mikrobizide Wirkstoffe
US9643922B2 (en) * 2008-08-18 2017-05-09 Yale University MIF modulators
EA201170349A1 (ru) * 2008-08-18 2011-08-30 Йейл Юниверсити Модуляторы mif
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
PE20120493A1 (es) 2009-06-29 2012-05-20 Incyte Corp Pirimidinonas como inhibidores de pi3k
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
TW201130842A (en) * 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
US8748626B2 (en) * 2010-04-15 2014-06-10 Novartis Ag Oxazole and thiazole compounds as KSP inhibitors
AU2011239977B2 (en) 2010-04-15 2014-11-27 Novartis Ag Triazole compounds as KSP inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
KR20230038593A (ko) 2011-09-02 2023-03-20 인사이트 홀딩스 코포레이션 Pi3k 억제제로서 헤테로시클릴아민
CN102627578B (zh) * 2011-10-20 2014-06-11 南京大学 苯基苄胺类化合物及其应用
JP5977837B2 (ja) 2011-12-21 2016-08-24 ノヴィラ・セラピューティクス・インコーポレイテッド B型肝炎抗ウイルス剤
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CN102603544A (zh) * 2012-04-06 2012-07-25 南京大学 一种抗炎化合物、其制备及其用途
MX373711B (es) 2012-08-28 2020-05-08 Janssen Sciences Ireland Uc Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b.
DK2961732T3 (en) 2013-02-28 2017-07-10 Janssen Sciences Ireland Uc SULFAMOYLARYLAMIDS AND USE THEREOF AS MEDICINES TO TREAT HEPATITIS B
CN105102451B (zh) 2013-04-03 2018-09-18 爱尔兰詹森科学公司 N-苯基-氨甲酰衍生物及其作为药物用于治疗乙型肝炎的用途
DK2997019T3 (en) 2013-05-17 2018-12-03 Janssen Sciences Ireland Uc SULFAMOYLTHIOPHENAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
WO2014200872A1 (en) 2013-06-09 2014-12-18 Rjs Biologics Llc Pharmaceutical compounds targeted by mif affinity-tethered moieties
KR102244937B1 (ko) 2013-07-25 2021-04-27 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 글리옥사미드 치환된 피롤아미드 유도체 및 b형 간염 치료용 의약으로서의 이의 용도
DK3060547T3 (en) 2013-10-23 2018-01-15 Janssen Sciences Ireland Uc CARBOXAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATMENT OF HEPATITS B
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
EP3102225B1 (en) 2014-02-05 2020-03-25 Novira Therapeutics Inc. Combination therapy for treatment of hbv infections
US11078193B2 (en) 2014-02-06 2021-08-03 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
PH12017501538B1 (en) 2015-02-27 2024-02-14 Incyte Holdings Corp Salts of p13k inhibitor and processes for their preparation
US9884831B2 (en) 2015-03-19 2018-02-06 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
TW201718496A (zh) 2015-09-29 2017-06-01 諾維拉治療公司 B型肝炎抗病毒劑之晶型
CN109640980A (zh) 2016-04-15 2019-04-16 诺维拉治疗公司 包含壳体装配抑制剂的组合和方法
WO2018081361A1 (en) * 2016-10-28 2018-05-03 Children's Hospital Medical Center Methods and compositions for treatment of myelodyspastic syndromes and/or acute myleoid leukemias
JP2021515769A (ja) 2018-03-14 2021-06-24 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カプシド集合調節剤の投薬レジメン
CN112469418A (zh) 2018-06-01 2021-03-09 因赛特公司 治疗pi3k相关病症的给药方案
MA55020A (fr) 2019-02-22 2021-12-29 Janssen Sciences Ireland Unlimited Co Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
AR119732A1 (es) 2019-05-06 2022-01-05 Janssen Sciences Ireland Unlimited Co Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb
WO2024099898A1 (en) * 2022-11-07 2024-05-16 Merck Patent Gmbh Substituted bi-and tricyclic hset inhibitors

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
JPH03200961A (ja) * 1989-10-03 1991-09-02 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
JPH04184433A (ja) * 1990-11-20 1992-07-01 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
JPH04321046A (ja) * 1991-02-15 1992-11-11 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料の処理方法
US5185450A (en) 1991-02-19 1993-02-09 University Of South Florida Tetrazolium compounds for cell viability assays
JP2847273B2 (ja) * 1991-11-22 1999-01-13 富士写真フイルム株式会社 カラー画像形成方法
JPH063775A (ja) * 1992-06-22 1994-01-14 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
US6489300B1 (en) 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
EP1165519A1 (en) 1999-04-02 2002-01-02 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
US6271241B1 (en) * 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US6358949B1 (en) 1999-04-02 2002-03-19 Neurogen Corporation Aryl and hetroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
DE60028227T2 (de) 1999-10-27 2007-03-29 Cytokinetics, Inc., South San Francisco Chinazolinone benutzende verfahren und zusammenstellungen
NZ523774A (en) 2000-08-01 2004-09-24 Sod Conseils Rech Applic Imidazolyl derivatives
AU2001296799A1 (en) 2000-10-06 2002-04-15 Neurogen Corporation Benzimidazole and indole derivatives as crf receptor modulators
WO2002046168A1 (en) * 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
EP1360180A1 (en) 2001-01-19 2003-11-12 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
EP1351671A1 (en) 2001-01-19 2003-10-15 Cytokinetics, Inc. Triphenylmethane kinesin inhibitors
WO2003039460A2 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
US6753428B2 (en) 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
DE60222302T2 (de) 2001-12-06 2008-05-29 Merck & Co., Inc. Inhibitoren von mitotischem kinesin
WO2003049527A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1551812B1 (en) 2001-12-06 2009-03-04 Merck & Co., Inc. Mitotic kinesin inhibitors
US7244723B2 (en) 2001-12-06 2007-07-17 Merck & Co., Inc. Substituted furopyrimidinones as a mitotic kinesin inhibitors
EP1481077B1 (en) 2001-12-06 2009-11-04 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2005532991A (ja) * 2002-01-10 2005-11-04 ニューロジェン・コーポレーション メラニン凝集ホルモン受容体リガンド:置換2−(4−ベンジル−ピペラジン−1−イルメチル)−及び2−(4−ベンジル−ジアゼパン−1−イルメチル)−1h−ベンゾイミダゾールアナログ
WO2003059289A2 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
CA2475879A1 (en) 2002-02-15 2003-08-28 Cytokinetics, Inc. Synthesis of quinazolinones
AU2003249597B2 (en) 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
AU2003270015A1 (en) 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
WO2003094839A2 (en) 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
EP1507534A4 (en) 2002-05-10 2006-11-08 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
EP1509507A4 (en) 2002-05-23 2006-09-13 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
EP1513820A4 (en) 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
PL374190A1 (en) 2002-06-14 2005-10-03 Merck & Co, Inc. Mitotic kinesin inhibitors
EP1515949B1 (en) 2002-06-14 2007-03-14 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2005537257A (ja) 2002-07-08 2005-12-08 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン結合部位
EP1539727B1 (en) 2002-07-17 2009-02-18 Cytokinetics, Inc. Compounds, compositions, and methods for treating cellular proliferative diseases
EP1537089A4 (en) 2002-07-23 2008-04-16 Cytokinetics Inc CONNECTIONS, COMPOSITIONS AND PROCEDURES
EP1539180A4 (en) 2002-08-21 2006-08-30 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
JP2005539062A (ja) 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
AU2003900608A0 (en) * 2003-02-11 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Hdac inhibitor
CA2526988A1 (en) * 2003-06-05 2005-01-06 Merck And Co., Inc. Substituted indoles and a process for preparing substituted indoles
JP2007509082A (ja) * 2003-10-22 2007-04-12 アルピダ エー/エス ペプチドデホルミラーゼ阻害剤としてのベンゾイミダゾール誘導体類およびそれらの使用
EP1807399A2 (en) 2004-10-19 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Indole and benzimidazole derivatives

Also Published As

Publication number Publication date
JP2008517057A (ja) 2008-05-22
US20080317744A1 (en) 2008-12-25
US7608723B2 (en) 2009-10-27
US20060084687A1 (en) 2006-04-20
WO2006049835A3 (en) 2007-11-22
CN101233115A (zh) 2008-07-30
AU2005301133A1 (en) 2006-05-11
EP1807399A2 (en) 2007-07-18
EP2275412A1 (en) 2011-01-19
BRPI0517314A (pt) 2008-10-07
US8008335B2 (en) 2011-08-30
RU2007118523A (ru) 2008-11-27
CA2584979A1 (en) 2006-05-11
WO2006049835A2 (en) 2006-05-11
KR20070072598A (ko) 2007-07-04

Similar Documents

Publication Publication Date Title
MX2007004699A (es) Derivados de indol y bencimidazol.
TW200612958A (en) Substituted imidazole derivatives
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
TW200801000A (en) Spiroindolinone derivatives
IL193620A0 (en) Spiroindolinone derivatives
MX2010003156A (es) Derivados de aril amida substituida con tetrazol y usos de los mismos.
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
MX2011013771A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17.
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
MX2012009186A (es) Pirrolidina-2-carboxamidas sustituidas.
TW200728307A (en) Novel spirochromanone derivatives
MX2009002735A (es) Derivados de oxindol como agentes anticancerigenos.
SI1753723T1 (sl) Substituirani kinolinski derivati kot mitotiäśni kinesinski inhibitorji
TN2009000178A1 (en) Substituted pyrazole and triazole compounds as ksp inhibitors
MY151295A (en) Pyrimidyl indoline compound
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
TW200800951A (en) Substituted imidazole compounds as KSP inhibitors
WO2007017728A3 (en) Novel heterocyclic compounds
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
MX2009013003A (es) Derivados de piperidina-amida.
MX2007004910A (es) Nuevos derivados de indol o benzimidazol.
IL188927A0 (en) Aryloxy quinolines and uses thereof as 5-ht6 modulators
TW200738697A (en) Benzimidazole derivatives as 5-HT6,5-HT24
MX2009001572A (es) Derivados de arilpiperazina y usos de los mismos.
MX2010008778A (es) Derivados de 3-alquil-piperazina y usos de la misma.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal